Axonics Modulation Technologies Inc (NASDAQ:AXNX) COO Rinda Sama sold 13,708 shares of Axonics Modulation Technologies stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $43.10, for a total value of $590,814.80. Following the sale, the chief operating officer now owns 171,293 shares of the company’s stock, valued at approximately $7,382,728.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Rinda Sama also recently made the following trade(s):

  • On Tuesday, July 21st, Rinda Sama sold 14,400 shares of Axonics Modulation Technologies stock. The shares were sold at an average price of $40.81, for a total value of $587,664.00.
  • On Tuesday, May 19th, Rinda Sama sold 20 shares of Axonics Modulation Technologies stock. The shares were sold at an average price of $39.00, for a total value of $780.00.

Shares of Axonics Modulation Technologies stock opened at $42.36 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.28 and a quick ratio of 9.31. The business’s 50 day simple moving average is $38.21 and its two-hundred day simple moving average is $33.44. The stock has a market capitalization of $1.46 billion, a P/E ratio of -15.40 and a beta of 0.17. Axonics Modulation Technologies Inc has a one year low of $15.25 and a one year high of $44.25.

Axonics Modulation Technologies (NASDAQ:AXNX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.17. The business had revenue of $26.30 million for the quarter, compared to analysts’ expectations of $14.47 million. Axonics Modulation Technologies had a negative return on equity of 57.95% and a negative net margin of 208.60%. The business’s quarterly revenue was up 2341.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.47) EPS. Sell-side analysts expect that Axonics Modulation Technologies Inc will post -1.95 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $48.00 price target on shares of Axonics Modulation Technologies in a research report on Monday, July 13th. BidaskClub downgraded Axonics Modulation Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, July 15th. Zacks Investment Research downgraded Axonics Modulation Technologies from a “buy” rating to a “hold” rating in a research report on Friday, June 5th. Morgan Stanley lifted their price target on Axonics Modulation Technologies from $36.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, SVB Leerink raised their price objective on Axonics Modulation Technologies from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Wednesday, July 22nd. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $43.40.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Axonics Modulation Technologies by 8.9% in the 1st quarter. BlackRock Inc. now owns 1,512,303 shares of the company’s stock worth $38,428,000 after purchasing an additional 123,303 shares during the period. AXA bought a new stake in shares of Axonics Modulation Technologies in the 1st quarter worth approximately $23,489,000. Lord Abbett & CO. LLC grew its position in shares of Axonics Modulation Technologies by 159.7% in the 1st quarter. Lord Abbett & CO. LLC now owns 802,631 shares of the company’s stock worth $20,395,000 after buying an additional 493,527 shares during the last quarter. Blackcrane Capital LLC grew its position in shares of Axonics Modulation Technologies by 66.4% in the 1st quarter. Blackcrane Capital LLC now owns 750,339 shares of the company’s stock worth $19,066,000 after buying an additional 299,339 shares during the last quarter. Finally, Samlyn Capital LLC grew its position in shares of Axonics Modulation Technologies by 30.8% in the 1st quarter. Samlyn Capital LLC now owns 677,390 shares of the company’s stock worth $17,212,000 after buying an additional 159,356 shares during the last quarter. 66.50% of the stock is currently owned by institutional investors and hedge funds.

Axonics Modulation Technologies Company Profile

Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.

Featured Story: FinTech

Insider Buying and Selling by Quarter for Axonics Modulation Technologies (NASDAQ:AXNX)

Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.